Objective To investigate the clinical efficacy and effect of sacubactril valsartan and dapagliflozin on renal function in patients with type 2 diabetic nephropathy(DN).Methods 68 patients with type 2 DN admitted to Yangkou Hospital of Rudong from January 2022 to January 2023 were selected as the study objects and were divided into con-trol group and observation group by random number table method,with 34 cases in each group.The control group was given single treatment of daglipzin,and the observation group was given combined treatment of daglipzin and sakuba-tril valsartan.The clinical effects,and renal function indexes,blood glucose changes,and oxidative stress indexes of the two groups were compared.Results The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,fasting plasma glucose(FPG)and glyeosylated hemoglobin A1c(HbA1c)in both groups decreased,and the increase were more significant in the ob-servation group,and the difference was statistically significant(all P<0.05).After treatment,blood urea nitrogen(BUN),serum creatinine(Scr)and 24-hour urinary protein quantity(24 hUTP)in both groups showed a decreasing trend,the glomerular filtration rate showed an increasing trend,and the change was more obvious in the observation group,and the difference was statistically significant(all P<0.05).After treatment,total antioxidant capacity(T-AOC),superoxide dismutase(SOD)and glutathione peroxidase(GSH-PX)in both groups showed an increasing trend,and the increasing range was greater in the observation group,and the difference was statistically significant(all P<0.05).Conclusion The combination of shabubactril valsartan and dagliprazin can achieve a definite effect in the treatment of type 2 DN patients,improve renal function,achieve good control of blood sugar,reduce inflammation and improve prognosis.
Sacubactril valsartanDapagliflozinType 2 diabetesKidney diseaseRenal function
NETL
NSTL
维普
万方数据
